Skip to main content
. 2006 Feb 28;94(6):798–805. doi: 10.1038/sj.bjc.6603011

Table 3. Second-line therapies.

  FOLFIRI
FOLFOXIRI
 
Second-line treatment No patients % No patients % P-value
Any 102 70 80 58 0.041
L-OHP based 92 63 39 28 0.029
CPT-11 based 10 6 14 10 NSa
Fluoropyrimidines 44 30 29 21 NS
Cetuximab 10 7 7 5 NS
a

NS, nonsignificant.